In addition, preclinical and clinical studies have shown that PARP-1 activity in cancer cells is critical for the establishment of resistance to genotoxic therapies [19, 20], suggesting that there is a real opportunity to combine PARPi with chemotherapy and radiotherapy [21, 22]. This evidence concerns the gene PARP1 and cancer.